Geusens P P M M, Lems W F
Academisch Ziekenhuis Maastricht, afd. Interne Geneeskunde/Reumatologie, Postbus 5800, 6202 AZ Maastricht.
Ned Tijdschr Geneeskd. 2007 Jun 30;151(26):1445-8.
A randomised, placebo-controlled study into the effects of the annual intravenous administration of zoledronic acid for the prevention of fractures in postmenopausal women with osteoporosis was recently published. Zoledronic acid, a bisphosphonate, inhibits osteoclasts. The study included 7765 patients with osteoporosis, between the ages of 65 and 89 years, who were given calcium and cholecalciferol daily by mouth in addition to 5 mg zoledronic acid or placebo once a year. Three infusions were given to 81% of the patients. Fewer fractures were seen in the study group than in the control group: after 3 years, hip fractures were reduced by 41%, non-vertebral fractures by 25% and vertebral fractures by 70%, already within one year (by 6o%). Side effects included acute phase reactions, atrial fibrillation, ocular complaints, renal-function disorders, and hypocalcaemia. Some examples of candidates for treatment with zoledronic acid would be patients with osteoporosis in whom oral treatment meets objections or who are hospitalised due to a fracture.
最近发表了一项随机、安慰剂对照研究，该研究旨在探讨每年静脉注射唑来膦酸对预防绝经后骨质疏松症女性骨折的效果。唑来膦酸是一种双膦酸盐，可抑制破骨细胞。该研究纳入了7765名年龄在65至89岁之间的骨质疏松症患者，这些患者除了每年接受一次5毫克唑来膦酸或安慰剂治疗外，每天还口服钙和胆钙化醇。81%的患者接受了三次输注。研究组的骨折发生率低于对照组：3年后，髋部骨折减少了41%，非椎体骨折减少了25%，椎体骨折减少了70%，在一年内就已减少（减少了60%）。副作用包括急性期反应、心房颤动、眼部不适、肾功能障碍和低钙血症。唑来膦酸治疗的候选患者示例包括口服治疗存在问题或因骨折住院的骨质疏松症患者。
